NCT03641313 2026-04-13
Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
On Target Laboratories, LLC
Mayo Clinic
Medtronic - MITG
S.L.A. Pharma AG
Roswell Park Cancer Institute